METABOLITES ACTIVITY OF ENDOPHYTIC STREPTOMYCES SP. IPBCC. B.15.1539 FROM TINOSPORA CRISPA L. MIERS: ALPHA-GLUCOSIDASE INHIBITOR AND ANTI-HYPERGLYCEMIC IN MICE

Objective: This research work aimed to assess the capability of endophytic Streptomyces sp. IPBCC. b.15.1539 isolated from Tinospora crispa inproducing α-glucosidase inhibitor compound and examined the effect of its ethyl acetate extract containing α glucosidase inhibitor in lowering blood glucose in streptozotozin mice.Methods: Streptomyces sp. IPBCC. b.15.1539 was grown in a bioreactor filled with International Streptomyces Project 2 medium, for 5, 10, 15, and20 days, and assayed for its in vitro α-glucosidase inhibitory activity. The ethyl acetate extract was examined for its IC50Results: The crude extract produced value. An in vivo experimentwas set up using thirty mice, which were divided into five treatment groups: (a) acarbose (0.03 mg/30 g body weight) used as a positive control, (b) placebo used as a negative control, (c-e) treatment groups were treated with ethyl acetate extract at 0.036 mg/30 g body weight (P1), 0.36 mg/30 gbody weight (P2), 0.036 mg/30 g body weight (P3).98.5% α-glucosidase inhibitory activity, with 15,6 biomass after 10 days of production. The ethyl acetateextract at a concentration of 1000 µg/ml produced 96.08% α-glucosidase inhibitory activity, while acarbose at the same concentration gave 97.46%inhibition. The IC50 for the ethyl acetate extractConclusions: The was 0.047 µg/ml, while for acarbose was 0.003 µg/ml. The ethyl acetate extract applied as the P1treatment group lowered blood glucose levels in streptozotozin mice by 26%. α-glucosidase inhibitor of Streptomyces sp. IPBCC. b.15.1539 of T. crispa has the potency as an antidiabetic agent for type 2 DMtherapy